Company Profile
Assembly Biosciences Stock Price, News & Analysis
Company overview
Business overview
Assembly Biosciences is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Assembly Biosciences is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
Assembly Biosciences follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, Assembly Biosciences sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Why the stock is moving
ASMB is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Assembly’s catalysts are its hepatitis B and antiviral platform, plus any update that shows the company can still create value from its RNA / small-molecule strategy. The company still needs a cleaner clinical path.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
- 02
Assembly Biosciences to Present at the BofA Securities 2026 Global Health Care Conference
Source: Assembly Biosciences
- 03
Assembly Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights
Source: Assembly Biosciences
- 04
- 05
Assembly Biosciences Announces Pricing of $175 Million in Equity Financings
Source: Assembly Biosciences
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.